Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Controlled Contamination Services Awarded ISO 9001:2015 Certification

For over 25 years, CCS has provided facility cleaning solutions, technical services and decontamination service to millions of square feet of sensitive client spaces throughout the United States. CCS tailors its solutions with proven best practices in facility services and cleaning controlled environments. To do so, we develop the optimal cleaning strategy for each situation by assembling the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

For over 25 years, CCS has provided facility cleaning solutions, technical services and decontamination service to millions of square feet of sensitive client spaces throughout the United States. CCS tailors its solutions with proven best practices in facility services and cleaning controlled environments. To do so, we develop the optimal cleaning strategy for each situation by assembling the right resources, processes, and expert personnel to ensure the integrity of your environments.

Our Commitment to Providing the Highest Quality Services

Controlled Contamination Services’ certification to the 9001 Standard demonstrates our commitment to providing the highest quality services to our clients. As a US-based provider of enterprise solutions for the pharmaceutical, biotech, medical device, High Tech, IT, and Aerospace and Defense industries, CCS provides its clients with comprehensive cleaning, bio-decontamination, and technical service solutions that exceed the health, safety and environmental requirements of its customers.

Meeting the International Standard for a Quality Management System

The ISO 9001 standard is the international standard that specifies requirements for a quality management system (QMS). Organizations use the standard to demonstrate the ability to consistently provide products and services that meet customer and regulatory requirements. It is the ultimate global benchmark for quality management—a critical tool for both CCS and the partnerships it creates with its customers.

Continuous improvement and High-Quality Service Delivery are fundamental values at CCS. CCS’ clients require detailed and accurate documentation as well as adherence to Good Manufacturing Practices and Good Documentation Practices. CCS works under some of the most rigorous procedures as specified by the FDA and other US regulatory agencies and has a long history of developing and improving procedures and processes as well as developing and maintaining these requirements for their clients.

Streamlining Efficiency to Contain Cost and Reduce Clients’ Total Spend

The ISO certification also provides CCS the opportunity to streamline efficiency, contain cost and total spend to its clients. In addition, it allows CCS the ability to continuously improve its consistency and information flow, time management, service delivery and service performance, customer service, accountability and tracking of key performance measurements, to the highest level possible.

CCS is the leading provider of integrated facility services for the Life Sciences, High Tech, IT, and Aerospace and Defense industries. One of our highest values as a company is quality and rigorous dedication to the needs of each of our unique clients. To learn more, please visit cleanroomcleaning.com.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512